Regeneron Pharmaceuticals Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Regeneron Pharmaceuticals Inc Unternehmen

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Regeneron Pharmaceuticals Inc Informationen



BörsenkürzelREGN

Name des UnternehmensRegeneron Pharmaceuticals Inc

IPO-datumApr 02, 1991

CEOSchleifer (Leonard S)

Anzahl der mitarbeiter15106

WertpapierartOrdinary Share

GeschäftsjahresendeApr 02

Addresse777 Old Saw Mill River Road

StadtTARRYTOWN

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl10591

Telefon17813705000

Websitehttps://www.regeneron.com/

BörsenkürzelREGN

IPO-datumApr 02, 1991

CEOSchleifer (Leonard S)

Führungskräfte von Regeneron Pharmaceuticals Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.13M

+14941.00%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

688.05K

+17578.00%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

52.18K

-2213.00%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

44.85K

+1080.00%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.17K

-743.00%

Mr. George L. Sing

Independent Director

33.06K

+155.00%

Mr. Christopher R. Fenimore

Chief Financial Officer, Executive Vice President - Finance

21.78K

+2035.00%

Mr. Arthur F. (Art) Ryan

Independent Director

17.81K

+155.00%

Ms. Marion E. McCourt

Executive Vice President - Commercial

14.49K

+119.00%

Dr. Michael S. Brown, M.D.

Independent Director

12.77K

+155.00%

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.13M

+14941.00%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

688.05K

+17578.00%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

52.18K

-2213.00%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

44.85K

+1080.00%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.17K

-743.00%

Mr. George L. Sing

Independent Director

33.06K

+155.00%

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Sanofi

1.62B

43.07%

EYLEA

680.60M

18.13%

EYLEA HD

430.60M

11.47%

Bayer

344.80M

9.18%

Libtayo

219.10M

5.84%

Andere

462.20M

12.31%

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Sanofi

1.62B

43.07%

EYLEA

680.60M

18.13%

EYLEA HD

430.60M

11.47%

Bayer

344.80M

9.18%

Libtayo

219.10M

5.84%

Andere

462.20M

12.31%

Aktionärsstatistik

Aktualisiert: Sun, Nov 16

Aktionäre

Aktionärstypen

Aktionäre

Anteil

The Vanguard Group, Inc.

8.73%

BlackRock Institutional Trust Company, N.A.

5.29%

State Street Investment Management (US)

4.54%

Dodge & Cox

4.41%

JP Morgan Asset Management

2.85%

Andere

74.18%

Aktionäre

Anteil

The Vanguard Group, Inc.

8.73%

BlackRock Institutional Trust Company, N.A.

5.29%

State Street Investment Management (US)

4.54%

Dodge & Cox

4.41%

JP Morgan Asset Management

2.85%

Andere

74.18%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

45.29%

Investment Advisor/Hedge Fund

31.13%

Hedge Fund

5.04%

Pension Fund

2.77%

Research Firm

2.72%

Bank and Trust

2.20%

Individual Investor

2.07%

Sovereign Wealth Fund

1.23%

Insurance Company

0.20%

Andere

7.36%

Institutionelle Beteiligung



Aktualisiert: Thu, Jan 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

2674

93.48M

90.51%

-2.18M

2025Q3

2596

94.26M

91.26%

-4.21M

2025Q2

2585

99.72M

95.69%

-2.03M

2025Q1

2621

99.84M

93.97%

-1.42M

2024Q4

2581

100.17M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.77M

92.44%

+388.23K

2023Q4

2406

98.50M

91.94%

-617.06K

2023Q3

2358

98.79M

92.52%

-1.71M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

9.00M

8.71%

-376.36K

-4.02%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

5.46M

5.29%

-204.21K

-3.60%

Sep 30, 2025

State Street Investment Management (US)

4.69M

4.54%

-140.78K

-2.91%

Sep 30, 2025

Dodge & Cox

4.55M

4.41%

+724.56K

+18.94%

Sep 30, 2025

JP Morgan Asset Management

2.95M

2.85%

+130.73K

+4.64%

Sep 30, 2025

Geode Capital Management, L.L.C.

2.54M

2.46%

+70.84K

+2.87%

Sep 30, 2025

Invesco Capital Management (QQQ Trust)

2.32M

2.24%

+133.61K

+6.12%

Dec 31, 2025

Putnam Investment Management, L.L.C.

2.15M

2.08%

+117.43K

+5.78%

Sep 30, 2025

Capital World Investors

2.00M

1.93%

+32.35K

+1.65%

Sep 30, 2025

Loomis, Sayles & Company, L.P.

1.98M

1.92%

+38.38K

+1.98%

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

ProShares Ultra Nasdaq Biotechnology

6.6%

Invesco Nasdaq Biotechnology ETF

6.55%

Amplify Weight Loss Drug & Treatment ETF

6.4%

iShares Biotechnology ETF

5.9%

Simplify Health Care ETF

5.54%

VanEck Biotech ETF

5.51%

Invesco Biotechnology & Genome ETF

5.4%

iShares Genomics Immunology and Healthcare ETF

4.97%

First Trust NASDAQ Pharmaceuticals ETF

4.36%

First Trust NYSE Arca Biotechnology Index Fund

3.88%

ProShares Ultra Nasdaq Biotechnology

Anteil6.6%

Invesco Nasdaq Biotechnology ETF

Anteil6.55%

Amplify Weight Loss Drug & Treatment ETF

Anteil6.4%

iShares Biotechnology ETF

Anteil5.9%

Simplify Health Care ETF

Anteil5.54%

VanEck Biotech ETF

Anteil5.51%

Invesco Biotechnology & Genome ETF

Anteil5.4%

iShares Genomics Immunology and Healthcare ETF

Anteil4.97%

First Trust NASDAQ Pharmaceuticals ETF

Anteil4.36%

First Trust NYSE Arca Biotechnology Index Fund

Anteil3.88%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Jan 30, 2026

REGN.NB Interim Cash Dividend of gross USD 0.94 paid on Mar 05, 2026 going ex on Feb 20, 2026

Feb 20, 2026

Mar 05, 2026

Feb 20, 2026

Feb 04, 2025

REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025

Feb 20, 2025

Mar 20, 2025

Feb 20, 2025

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten